GARDASIL 9 (vaccin papillomavirus humain 9-valent, recombinant, adsorbé)
Reason for request
- Key points
Favourable opinion for reimbursement in the prevention of infections and lesions due to certain oncogenic types of Human Papillomavirus (HPV), in girls and boys, in accordance with the conditions defined in the current vaccine schedule.
- What therapeutic improvement?
Therapeutic improvement in the strategy for the prevention of premalignant anogenital lesions and cancers associated with certain types of HPV in the populations (girls and boys) and in accordance with the recommended conditions.
- Role in the care pathway?
In accordance with current national recommendations, GARDASIL 9 (nonavalent recombinant vaccine against HPV infections) can be used in the context of its MA for the following populations:
- all girls and boys from 11 up to and including 14 years of age, with catch-up vaccination possible for all adolescents and young adults (men and women) from 15 up to and including 19 years of age;
- men who have sex with men (MSM) up to 26 years of age.
Role of the medicinal product in the care pathway
The preferential use of the GARDASIL 9 vaccine is recommended since it contains nine HPV valences, whereas the GARDASIL vaccine contains four and the CERVARIX vaccine contains two. However, in the absence of interchangeability data, it is recommended that the whole vaccination course be completed using the same vaccine (CERVARIX or GARDASIL or GARDASIL 9).
The clinical benefit of GARDASIL 9 is substantial in the MA indication and for the populations (girls and boys) recommended following the HAS opinion of December 2019.
Clinical Added Value
the Committee considers that GARDASIL 9 provides a moderate clinical added value (CAV III) - in the same way as GARDASIL on its initial assessment in girls - in the strategy for the prevention of premalignant anogenital lesions and cancers associated with certain types of HPV in the populations (girls and boys) and in accordance with the recommended conditions.